Skip to content

Valneva

  • About Us
    About Us Advancing vaccines for better lives Learn More
    • Our Strategy
    • Our Responsibility
    • Our Team
  • Products
    Products Focusing on vaccines for infectious diseases with major unmet needs. Learn More
    • Japanese Encephalitis Vaccine
    • Cholera Vaccine
    • Marketing and Distribution
    • Manufacturing and Services
  • R&D
    R&D Dedicated to innovation in vaccine research and development. Learn More
    • Pipeline
    • Lyme Disease – VLA15
    • Chikungunya – VLA1553
    • COVID-19 – VLA2001
    • Zika – VLA1601
    • Clostridium Difficile – VLA84
    • Expanded Access Policy
    • Scientific Publications
  • Investors
    Investors Learn More
    • Events and Presentations
      • Calendar
      • Corporate Presentations
    • Financial & Filings
      • Financial Reports
      • SEC Filings
    • Press Releases
    • Corporate Governance
      • Corporate Governance
      • Corporate Compliance & Ethics
    • Regulated Information
    • Stock Information
      • Stock Price
      • Analysts
      • Shareholder Structure
      • Vienna Stock Exchange Delisting
    • General Meetings
      • 2022 Combined General Meeting
      • June 23, 2022 Special Meeting
      • General Meeting Archive
    • Videos and Webcasts
    • FAQ
    • Contact
  • Media
    Media Press releases, latest news and media resources Learn More
    • Press Releases
    • In The News
    • Media Kit
    • Media Contacts
  • Careers
Contact
  • EN
  • FR
  • | DE
Search

Press Releases

March 24, 2022

Valneva Announces Filing of 2021 Universal Registration Document and US Form 20-F

March 24, 2022

Valneva Reports Full Year 2021 Results and Provides Corporate Updates

March 16, 2022

Valneva Announces Renewal of the Term of Office of its Management Board Members

March 11, 2022

Valneva Provides Regulatory Update on its COVID-19 Vaccine Candidate

March 8, 2022

Valneva Successfully Completes Pivotal Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate

March 1, 2022

Valneva Receives Emergency Use Authorization from Bahrain for its Inactivated COVID-19 Vaccine VLA2001

February 25, 2022

Valneva Receives Initial CHMP Assessment of its Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001

February 21, 2022

Valneva Awarded Up to £20 Million by Scottish Enterprise to Advance Vaccine Development

February 4, 2022

Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

February 3, 2022

Valneva Reports Full Year 2021 Revenue and Cash; Provides First 2022 Guidance

  • 1
  • 2
  • 3
  • 4
  • …
  • 45

Valneva

  • About Us
  • Products
  • R&D
  • Investors
  • Media
  • Careers
Related Websites
  • Valneva Canada
  • Valneva UK
  • Valneva Austria
  • Valneva USA
  • Valneva Nordic
  • Valneva France
Contact
© 2022 Valneva SE. All rights reserved.
  • Legal Notice
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • 1907-00-VLA-002 | 11-JUL-2019
We use cookies to improve the functionality and user experience of the website and to analyse the traffic. You can find detailed information in our Privacy Policy.
ACCEPT CHANGE MY PREFERENCES
Privacy & Cookies Policy

Your privacy is important to us

Cookies are very small text files that are stored on your computer when you visit a website. We use cookies for a variety of purposes and to enhance your online experience on our website (for example, to remember your account login details).

You can change your preferences and decline certain types of cookies to be stored on your computer while browsing our website. You can also remove any cookies already stored on your computer, but keep in mind that deleting cookies may prevent you from using parts of our website.

More information

For any queries in relation to our policy on cookies and your choices, please contact us.

To find out more, please visit our Cookies Policy.
Strictly necessary cookies
Always Enabled
These cookies are essential to provide you with services available through our website and to enable you to use certain features of our website.

Without these cookies, we cannot provide you certain services on our website.
Tracking and performance cookies
These cookies are used to collect information to analyze the traffic to our website and how visitors are using our website.

For example, these cookies may track things such as how long you spend on the website or the pages you visit which helps us to understand how we can improve our website site for you.

The information collected through these tracking and performance cookies do not identify any individual visitor.
SAVE & ACCEPT